FORMA THERAPEUTICS HOLDINGS (FMTX) Stock Price & Overview
NASDAQ:FMTX • US34633R1041
Current stock price
The current stock price of FMTX is 20.01 USD. Today FMTX is up by 0.15%. In the past month the price increased by 0.2%. In the past year, price increased by 10.61%.
FMTX Key Statistics
- Market Cap
- 957.531M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.00
- Dividend Yield
- N/A
FMTX Stock Performance
FMTX Stock Chart
FMTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FMTX. When comparing the yearly performance of all stocks, FMTX is one of the better performing stocks in the market, outperforming 99.11% of all stocks.
FMTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FMTX. While FMTX has a great health rating, there are worries on its profitability.
FMTX Earnings
FMTX Forecast & Estimates
12 analysts have analysed FMTX and the average price target is 21.01 USD. This implies a price increase of 5.01% is expected in the next year compared to the current price of 20.01.
FMTX Groups
Sector & Classification
FMTX Financial Highlights
Over the last trailing twelve months FMTX reported a non-GAAP Earnings per Share(EPS) of -4. The EPS decreased by -32.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.02% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
FMTX Ownership
FMTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.34 | 370.255B | ||
| AMGN | AMGEN INC | 15.35 | 188.011B | ||
| GILD | GILEAD SCIENCES INC | 15.4 | 166.661B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.73 | 110.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.04 | 77.991B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.088B | ||
| INSM | INSMED INC | N/A | 31.319B | ||
| BIIB | BIOGEN INC | 11.65 | 26.98B | ||
| NTRA | NATERA INC | N/A | 25.887B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.76 | 22.916B | ||
| MRNA | MODERNA INC | N/A | 19.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.333B | ||
| INCY | INCYTE CORP | 11.85 | 17.971B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FMTX
Company Profile
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 189 full-time employees. The company went IPO on 2020-06-16. The firm is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.
Company Info
IPO: 2020-06-16
FORMA THERAPEUTICS HOLDINGS
300 North Beacon Street, Suite 501
Watertown MASSACHUSETTS 02472 US
CEO: Frank D. Lee
Employees: 189
Phone: 16176791970.0
FORMA THERAPEUTICS HOLDINGS / FMTX FAQ
Can you describe the business of FORMA THERAPEUTICS HOLDINGS?
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Watertown, Massachusetts and currently employs 189 full-time employees. The company went IPO on 2020-06-16. The firm is focused on the development and commercialization of therapeutics for patients with hematologic diseases and cancers. Its pipeline consists of six product candidates. Its product candidates include etavopivat, FT-7051, Olutasidenib- Acute Myeloid Leukemia IDH1m inhibitor, and Olutasidenib Glioma IDH1m inhibitor. Its lead product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy for the treatment of sickle cell disease (SCD), and other hemoglobinopathies. Its product candidate, FT-7051, is an inhibitor of CREB-binding protein/E1A binding protein p300, or CBP/p300 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Olutasidenib is an oral, selective small molecule investigational agent designed to selectively bind to and inhibit mutated IDH1 enzymes.
What is the stock price of FORMA THERAPEUTICS HOLDINGS today?
The current stock price of FMTX is 20.01 USD. The price increased by 0.15% in the last trading session.
Does FMTX stock pay dividends?
FMTX does not pay a dividend.
What is the ChartMill rating of FORMA THERAPEUTICS HOLDINGS stock?
FMTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about FORMA THERAPEUTICS HOLDINGS (FMTX) stock?
12 analysts have analysed FMTX and the average price target is 21.01 USD. This implies a price increase of 5.01% is expected in the next year compared to the current price of 20.01.
Can you provide the number of employees for FORMA THERAPEUTICS HOLDINGS?
FORMA THERAPEUTICS HOLDINGS (FMTX) currently has 189 employees.
Can you provide the ownership details for FMTX stock?
You can find the ownership structure of FORMA THERAPEUTICS HOLDINGS (FMTX) on the Ownership tab.